In a first-in-human trial of patients with solid tumors, a MYC inhibitor appeared tolerable and enabled nearly half of evaluable patients to maintain stable disease.
All articles by Andrea S. Blevins Primeau, PhD, MBA
In a meta-analysis, nearly all patients with esophageal cancer who received neoadjuvant immunotherapy plus chemotherapy achieved R0 resection.
Researchers sought to determine whether implementing inpatient oncologist-led teams could reduce readmission rates and improved discharge to hospice.
Adding stereotactic body radiation therapy to sorafenib improves survival outcomes in patients with advanced hepatocellular carcinoma, a phase 3 trial suggests.
A diagnosis of PCOS was associated with a 1.9-fold higher risk of pancreatic cancer in a case-control study.
Patients with diverticular disease had an increased risk of lung, prostate, breast, hematologic, colorectal, gastric, liver, and pancreatic cancers.
Adding liposomal irinotecan to 5-fluorouracil and leucovorin can improve outcomes in gemcitabine-refractory, advanced pancreatic cancer, a phase 3 study suggests.
Adding pembrolizumab to lenvatinib does not improve outcomes in patients with advanced hepatocellular carcinoma, results of the LEAP-002 study suggest.
Individuals who are overweight or obese, or who become overweight or obese over time, have a higher risk of liver cancer and biliary tract cancer.
The incidence of cholangiocarcinoma has increased in recent years, and this increase is not fully explained by disease reclassification.